A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)
23HVI3827 | Post-ACS | 70033093ACS3003
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Apply Now